A phase 1/2 study of ixazomib as a replacement for bortezomib or carfilzomib for multiple myeloma patients recently relapsed or refractory to their last combination regimen containing either bortezomib or carfilzomib
BACKGROUND: Multiple myeloma is a rare form of cancer that affects the proper function of plasma cells in the immune system. Patients experience symptoms ranging from bone pain to otherwise avoidable infections that can have negative effects on quality of life. Despite advances in multiple myeloma t...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/41248 |